Article

Completed Clinical Trials of p53 Gene Therapy in Cancer: A ClinicalTrials.gov-Based Analysis

2025-08-27

Abstract excerpt

<title>Abstract</title> <p>Background The tumour suppressor gene TP53, frequently mutated in various different types of cancers, plays a vital role in regulating cell cycle arrest, apoptosis, and genomic stability. Gene therapy targeting p53 aims to restore its normal function in tumours with defective p53, offering a novel therapeutic approach. Objective This study aims to systematically characterise the design,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8f7572dd-8464-5dc4-93dd-2a24140953c7
DOI: 10.21203/rs.3.rs-7240665/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Completed Clinical Trials of p53 Gene Therapy in Cancer: A ClinicalTrials.gov-Based AnalysisDOI 10.21203/rs.3.rs-7240665/v1Read

Will therapies that target tumour suppressor genes be useful in cancer treatment?Semantic proximity Read

Technology evaluation: Sch-58500, Canji.Semantic proximity Read

Adenovirus p53 gene therapySemantic proximity Read

Methods for screening tumors for p53 status and therapeutic exploitation.Semantic proximity Read

Strategies for therapeutic targeting of the p53 pathway in cancer.Semantic proximity Read

The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer.Semantic proximity Read

p53 as the Focus of Gene Therapy: Past, Present and Future.Semantic proximity Read

TP53 in Biology and Treatment of OsteosarcomaSemantic proximity Read

Key points of basic theories and clinical practice in rAd-p53 (Gendicine™) gene therapy for solid malignant tumorsSemantic proximity Read

Innovative Drug and Prodrug Candidates in Cancer Treatment Targeting TP53 Mutations: Challenge and Hope.Semantic proximity Read

Gene therapy clinical trials worldwide to 2017: An updateSemantic proximity Read

PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a TP53 Y220C mutation.Semantic proximity Read